DAG Ventures led the round, which included investments from previous investors Kleiner Perkins Caufield & Byers, New Science Ventures, Integral Capital Partners, Aperture Venture Partners and Cross Creek Capital.
Kevin Larkin, CEO of TherOx, said: “This financing continues to demonstrate the strong investor support for our proprietary SuperSaturated Oxygen Therapy targeted initially at the large market of severe heart attack patients. We believe SuperSaturated Oxygen Therapy will provide interventional cardiologists with the first treatment option following a successful intervention with a balloon angioplasty and stent that salvages the heart muscle in heart attack patients.”